375 related articles for article (PubMed ID: 28662309)
1. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
2. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
3. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
Lemal R; Fouquet G; Terriou L; Vaes M; Livideanu CB; Frenzel L; Barete S; Canioni D; Lhermitte L; Rossignol J; Arock M; Dubreuil P; Lortholary O; Hermine O
J Allergy Clin Immunol Pract; 2019; 7(7):2387-2395.e3. PubMed ID: 30954641
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).
Distler M; Maul JT; Steiner UC; Jandus P; Kolios AGA; Murer C; Graf N; Seebach JD; Pichler WJ; Navarini AA; French LE; Helbling A; Schmid-Grendelmeier P
Dermatology; 2020; 236(6):529-539. PubMed ID: 31958790
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.
Bossi G; Brazzelli V; De Amici M; Pietra D; Raviola C; Naso M; Regalbuto C; Boselli F; Fortina V; Marseglia GL
Ital J Pediatr; 2023 Jan; 49(1):6. PubMed ID: 36639823
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis.
Carter MC; Maric I; Brittain EH; Bai Y; Lumbard K; Bolan H; Cantave D; Scott LM; Metcalfe DD
J Allergy Clin Immunol; 2021 Mar; 147(3):1004-1010.e2. PubMed ID: 33220353
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab in the treatment of adult patients with mastocytosis: A systematic review.
Jendoubi F; Gaudenzio N; Gallini A; Negretto M; Paul C; Bulai Livideanu C
Clin Exp Allergy; 2020 Jun; 50(6):654-661. PubMed ID: 32107810
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
[TBL] [Abstract][Full Text] [Related]
10. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
Constantine GM; Bressler PB; Petroni D; Metcalfe DD; Carter MC
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1314-1316. PubMed ID: 30149096
[No Abstract] [Full Text] [Related]
11. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis.
Giannetti MP; Weller E; Bormans C; Novak P; Hamilton MJ; Castells M
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):655-660. PubMed ID: 33465452
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of omalizumab in Cutaneous Mastocytosis: A case series.
Hinojosa T; Lewis DJ; Vangipuram R; Safeer L; Mui UN; Haley C; Konoplev S; Tyring SK
Dermatol Ther; 2019 May; 32(3):e12848. PubMed ID: 30697883
[TBL] [Abstract][Full Text] [Related]
14. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
[No Abstract] [Full Text] [Related]
17. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium.
Pyatilova P; Akin C; Alvarez-Twose I; Arock M; Bonadonna P; Brockow K; Butterfield JH; Broesby-Olsen S; Carter MC; Castells M; George TI; Gotlib J; Greiner G; Gülen T; Hartmann K; Hermine O; Horny HP; Jawhar M; Lange M; Lyons JJ; Maurer M; Metcalfe DD; Nedoszytko B; Niedoszytko M; Orfao A; Reiter A; Schwaab J; Sotlar K; Sperr WR; Triggiani M; Valent P; Siebenhaar F
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2015-2024. PubMed ID: 35724950
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
Douglass JA; Carroll K; Voskamp A; Bourke P; Wei A; O'Hehir RE
Allergy; 2010 Jul; 65(7):926-7. PubMed ID: 19889117
[No Abstract] [Full Text] [Related]
19. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
Akin C; Arock M; Valent P
J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
[TBL] [Abstract][Full Text] [Related]
20. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre.
Hermans MAW; Rietveld MJA; van Laar JAM; Dalm VASH; Verburg M; Pasmans SGMA; Gerth van Wijk R; van Hagen PM; van Daele PLA
Eur J Intern Med; 2016 May; 30():25-30. PubMed ID: 26809706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
